(Q50540750)

English

[Photochemical inactivation of pathogens in platelets and plasma: five years of clinical use in routine and hemovigilance. Towards a change of paradigm in transfusion safety].

scientific article published on 6 April 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21474358

1 reference

Europe PubMed Central

[Photochemical inactivation of pathogens in platelets and plasma: five years of clinical use in routine and hemovigilance. Towards a change of paradigm in transfusion safety]. (English)

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21474358

author name string

J-P Cazenave

1

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21474358

publication date

6 April 2011

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21474358

Transfusion Clinique et Biologique

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21474358

18

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21474358

2

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21474358

53-61

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21474358

The hazards of blood transfusion in historical perspective

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2011.02.023

7 January 2021

Pathogen reduction: a precautionary principle paradigm.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2011.02.023

7 January 2021

Research opportunities for pathogen reduction/inactivation of blood components: summary of an NHLBI workshop.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2011.02.023

7 January 2021

Pathogen inactivation: making decisions about new technologies - preliminary report of a consensus conference.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2011.02.023

7 January 2021

Proceedings of a Consensus Conference: pathogen inactivation-making decisions about new technologies

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2011.02.023

7 January 2021

Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2011.02.023

7 January 2021

Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBC.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2011.02.023

7 January 2021

[Evolution of techniques for preparation of labile blood products (LBP): pathogen inactivation in LBP].

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2011.02.023

7 January 2021

Emerging infectious disease agents and their potential threat to transfusion safety

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2011.02.023

7 January 2021

Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2011.02.023

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2011.02.023

7 January 2021

Preserving blood safety against emerging retroviruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2011.02.023

7 January 2021

Human herpesvirus-8: what (not) to do redux?

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2011.02.023

7 January 2021

Chikungunya outbreaks--the globalization of vectorborne diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2011.02.023

7 January 2021

Transfusion-transmitted arboviruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2011.02.023

7 January 2021

West Nile virus (WNV): generalities and implications for blood transfusion

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2011.02.023

7 January 2021

Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La Réunion

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2011.02.023

7 January 2021

An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2011.02.023

7 January 2021

Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2011.02.023

7 January 2021

Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2011.02.023

7 January 2021

Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2011.02.023

7 January 2021

Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2011.02.023

7 January 2021

Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2011.02.023

7 January 2021

Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2011.02.023

7 January 2021

An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2011.02.023

7 January 2021

Equipoise and the Dilemma of Randomized Clinical Trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2011.02.023

7 January 2021

Emerging and re-emerging viruses in the era of globalisation

1 reference

https://pubmed.ncbi.nlm.nih.gov/21474358

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21474358

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical Medical Research Award. Hepatitis C virus and eliminating post-transfusion hepatitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21474358

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA

1 reference

https://pubmed.ncbi.nlm.nih.gov/21474358

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction

1 reference

https://pubmed.ncbi.nlm.nih.gov/21474358

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of platelet transfusion clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/21474358

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Chikungunya epidemic in Italy and its repercussion on the blood system

1 reference

https://pubmed.ncbi.nlm.nih.gov/21474358

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Pathogen inactivation in labile blood products: transfusion safety and economic impact].

1 reference

https://pubmed.ncbi.nlm.nih.gov/21474358

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.TRACLI.2011.02.023

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21474358

0 references

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21474358

Semantic Scholar corpus ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50540750&oldid=1408927042"